AstraZeneca Pharma India has reported a strong 30% year-on-year growth in the second quarter of FY2026-27, with revenue from ...

Brazil's health regulator ANVISA approved Dr. Reddy's Laboratories to market a generic semaglutide injection for adults with ...

Supriya Lifescience Ltd. reported a standalone net profit of Rs. 29.25 crore for the second quarter ended September 30, 2026, ...

The biopharma division of IGL reported net revenue of Rs 246 crore, EBITDA of Rs 29 crore and a gross margin of 40.1% in FY26 ...

The company's consolidated total revenue from operations for the July–September quarter fell 29.8% to Rs. 4,247.32 crore ...

Its Rs 280 crore capital expenditure programme remains on track for completion by FY27, with Rs 160 crore already deployed ...

Alembic Pharmaceuticals Limited reported a massive 81% year-on-year surge in consolidated profit after tax (PAT) to Rs. 335 ...

Biocon Limited reported consolidated operating revenue of Rs 4,389 crore for the second quarter of FY27, up 2% year-on-year ...

Novo Nordisk has raised its full-year 2026 outlook for adjusted sales and operating profit following a stronger-than-expected ...

Sevabertinib is an oral, reversible, small-molecule tyrosine kinase inhibitor (TKI) designed to target HER2-activating ...

Operating performance also strengthened significantly, with consolidated EBITDA climbing 55% year-on-year to Rs 36.52 crore Hester Biosciences has reported a robust 44% year-on-year jump in ...

The expanded collaboration combines DifGen’s development and US manufacturing capabilities with Alembic’s established US ...